Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageElevance Health and its direct and indirect subsidiaries, referred to throughout this document as “we,” “us,” “our,” the “Company” or “Elevance Health,” is a leading health company bringing together the concepts of elevate and advance. We are focused on enhancing well-being and advancing health outcomes by delivering integrated, whole health solutions across the care journey. We support consumers throughout their full health journeys with medical, pharmacy, and behavioral health services designed to address their whole health needs.
In the company’s own words · 10-K filed Feb 6, 2026 · SEC EDGAR
Business segments
Q2 2026 · $56.74BThe company’s own SEC segment disclosure.
- Reportable$50.47B89%
- Carelon Rx$6.26B11%
Elevance Health (ELV) reported revenue of $50.5B in Q2 2026 (quarter ended June 30, 2026), up 1.4% from the same quarter a year earlier. That came with a gross margin of 89% and net income of $1.46B (2.9% of revenue). For the full year FY2025, revenue was $199.1B (+12% year on year) and net income $5.66B. Its largest segment in 2026-Q2 was Reportable at $50.5B, 89% of the disclosed total, just ahead of Carelon Rx at 11%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Healthcare Plans
Ranks #4 of 11 by Smart Score